Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Nspx has been quiet, however still think this is setting up for a breakout to up side soon. Could be wrong, the ticker has had many opportunities to tank and follow past movements to subs but seems to be holding up OK. Just treading water at or around the .02 level. RSI not overbought or oversold at the present so a movement may be be coming. The daily chart seems to be favoring a break up so we'll see. IMO
Don't really care why.. just good to see some green!
The nspx story may be far from over .. with the possibility of RT-AR001 as an adjunct or combination therapy with immunotherapy drugs and continued interest in thapsigargin (mipsagargins main ingredient) as antiviral and/or cancer drug anything can happen.
It seems cancer therapies are moving away from general chemotherapy and targeted cancer therapy (mipsagargin) to immunotherapy. Keytruda (immunotherapy) is or soon will be the largest selling cancer drug in the world.
That's a good question. However, when you look at the original agreement between Ridgeway and Inspyr in 9/18, it seems that Ridgeway was only interested in the adenosine platform and did in fact complete what they said they were going to do and expanded the platform to the RT-AR001 platform they are now touting. In fact, I don't think anything has been done by the company on mipsagargin since 2/18 when Lowe shut down operations and closed any clinical studies and research agreements. It seems that Inspyr is relying on outside research (primarily concerning thasigargin) for continued clinical positives that may relate to mipsagargin getting attention. (recent U of Nottingham report).
I think NSPX has chosen RT-AR001 as the focus over mipsagargin only because they don't have the resources on two fronts and RT-AR001 as an adjunct therapy would have an easier and less time consuming($$$) path to profitability. Just my opinion.
Craig Dionne now that's a blast from the past. In a interview 4/2015:
Results from Phase II of this new drug treatment are showing promising results, GenSpera (www.genspera.com) is planning phase three testing for 2016, which could put mipsagargin on track for FDA approval for widespread use in 2018. "Cancer can't escape OUR drug. There is no way to get around it," Dionne says.
Dr. Craig Dionne is well on his way to be becoming the Steve Jobs of the bio tech world. In Alan Dukes new interview with Dr. Dionne he compares his accomplishments in cancer research, passion for finding a cure, and his creative innovative approach on par with other technological innovators –including Elon Musk, Jeff Bezos and Larry Page.
Confidence was not his problem but over promising drug results and under producing was his down fall. Led many down a very regretful path (me for one). File in: Don't believe all you read or hear from experts.
Just like past slides.. the company never makes an effort to defend the PPS against the constant sellers. They have always just let it tank to subs. We actually know nothing about what is happening with the company. In October Ridgeway took over with 65,000,000 shares you would logically thing that an effort by Hislop to increase the value of his holdings would take place but it seems its business as usual. An effort to get some buyers need to take place soon. Eventually it may get oversold and a bounce may happen but without the company participating a sustained surge is not likely!
This ticker has been frustrating for sure.. these slow slides from spikes are common and equally as frustrating. What is particularly maddening is that the company gives zero support for the share price moving forward. Because NSPX outsources everything Its my gut feeling that no one is actually running the company and all R&D and company functions are in the hands of third parties. Also scary is that Sabby is controlling the share price in an effort to get convertible loans paid off. It may be as simple as there is no 8-K worthy news to report and when there is some it will be announced but trying to get anyone attention to give updates has been tried over and over again with no success.
I thought 2020 10-K was due but was wrong.. not due until 90 days after year so march 31 is due date for 2020 10-K... my bad!
Not much to smile about this week other than it had many chances to totally tank and held up (sort of). Since it is not in sub pennies (yet) with the amount of shares out there is somewhat positive and volume on down slide has been light. This could run fast on two fronts with a serious update on either RT-AR001 or Mipsagargin. Anyway, hold and wait as usual is the mantra of the day!
Wrong Michael Cain.. our Michael Cain is not so accomplished. From NSPX
8-K 8/2019 .. Michael Cain, 35 has over 15 years of experience in technology and computer consulting fields. Mr. Cain serves as the President and as a Board member of Level 4 Services, Inc, a private information technology company since 2013. In evaluating Mr. Cain’s specific experience, qualifications, attributes and skills in connection with his appointment to our Board, we took into account his management experience in other organizations and business development background
Since his hire in July 2019 he has not said or posted a word concerning the goings on of NSPX. Many feel that this man does not actually exist.
Yeah man! Don't let recent slide, trades or lack of noise cloud the fact that NSPX is setting up for next major spike. 2020 10-K due next week.. maybe something?
Looked closely at the recent accesswire post of 2/18. The study related in footnote 1 that adenosine inhibitors may have benefit as a supplement or added drug to assist current Immunotherapy drugs in decease therapy. Current Immunotherapy drugs (PD(L)1 checkpoint inhibitors are growing popular as a treatment for various cancers. As noted in the accesswire post RT-AR001 may get involved as adjunct therapies with these immunotherapy drugs. The noted PD(L)1 drug Keytruda leads the field as noted in resent GlobalData Analysis: That significant activity in cancer is the reason Keytruda is projected to generate $22.5 billion in revenue by 2025, according to an analysis by GlobalData, a data and analytics company. Keytruda may become largest dollar selling drug in the world!
You might already know.. Cain is president of Level4services, Calabasas ca,
Scott Ogilivie is chairman of Formula Four Beverages and a professional paid Company Director for hire. Clair Thom I believe is retired and also a for hire director. Dr. Hislop just changed his Linked page from president and ceo of ridgeway to SVP of Eiger. Other than Hislop I don't think any of them have any idea of what's going on with the company. Unfortunately, it looks like the business golden rule is in place that "he who has the gold makes the rules" and that is Hal Mintz (Sabby). I'm pretty sure he was behind the AS going to 1 billion in exchange for continue funding so he could keep converting shares. Good Luck in trying to get thru to any of these guys!
What can you say.. other than International plans and patents don't garnish much value.. second time (12/10) they posted about global strategy and both times same result ... Yawn! However, good to see they are trying to expand market and do something.
You would think that Ridgeway CEO Dr. Hislop who is sitting on 65,000,000 shares would do everything in his power to get the share price up so it most be Sabby who is controlling the movement of the price. Once the convertible debt is taken care of maybe things will change. Unfortunately, we may get a maxed out AS and ripe for another RS.. this ticker has had 3 of them already.
With a non-existent Board, a figurehead CEO, Sabby controlling the finances, all research designated to independent scientists and Hislop working full time as SVP of Eiger it is puzzling to find anyone who would take the time to answer any pertinent questions concerning the ticker. I have long ago come to the conclusion that the only news that I want to hear is that NSPX has been sold or at least one or more of the drug platforms has been sold or a partnering agreement has been entered with a legitimate pharm company to advance the drug platforms.
Always liked the "will provide timely updates to shareholders". Holdover from the Chris Lowe days
Some help from Dr. Hislop would certainly be welcomed at any time now. There are drug platforms in the NSPX portfolio that with positive news would break this ticker out in a substantial way. We are ready bring it on!
Soft day with sellers in control.. need to hold it's ground and find some buyers or the nspx slide from the 2/9 high of .057 will continue. Seen the retreats from spikes many times before.
It's more than odd.. it's baffling that since 2016 when Chris Lowe took over the company that the ticker has been virtually silent. While all CEO's have stated that there will be transparency and communication to stakeholders but nothing has been farther from the truth. All communication has been thru sec filings and any news has never actually been attributed to the company but shadow postings from questionable sources, the internet or scientific research studies. Hang the hat on the fact that Ridgeway owns 65,000,000 shares worth 1.7 million today. If RT-AR001 is the drug they say it is that 65,000,000 shares will be worth a multiple of todays price. Also, thapsigargin along with mipsagargin although totally forgotten by the company may be getting some attention for their role in COVID as per the current research. It's been a frustrating ride and don't expect anything different going forward.
Yes there are many that have been here awhile! I bought genspera in 2010 and have been in and out of this stock a few times over the yrs. I still hold a substantial amount of shares only because I feel that mipsagargin will eventually show real value. Never tried to reach out to anyone in the company because I would not expect them to give any non- public info that had value!
I do agree with Sabby involved that there is certain dilution so they have shares to convert and sell. They lend the money for that purpose. They also own shares in accounts and Ridgeway is on record to own 65,000,000 shares. The real money is in PPS going up. These spikes and retreats are common for this ticker. Until the COMPANY announces not these peripheral research articles that a situation is in the works that produces actual $$$ value for the company thru their drug platforms this is what we have. The last update was 12/10 and noted patent expansion and world wide market expansion to Asia Europe etc. It left more questions than answers.. Pure garbage!
This space is to post news/information and opinions concerning the ticker NSPX. Everyone's opinion is taken and informative decisions should be made to formulate the direction investors need or want to go. NSPX has been a frustrating ride for sure and where it is going is still up in the air. No one really cares about the financial prowess or situation of posters and mainly concentrate on the financial situation of their own account.
That has been their action in the past. No doubt that they may be heading in that direction again. Lots of shares have traded recently!
You have been here long enough to see many on many posters who at times were totally enthusiastic concerning this ticker and bailed with their profits or loses. They all have the rite to buy, sell or hold and do what they feel is the best for their account. Long term buy and hold in this ticker is a frustrating wait and see. Not many put up with it when other opportunities are available or should they. I personally think the drug platforms will show value and can wait it out. Trading pennies is mot my interest!
As 17 says this stock is good at creating bag holders. The brave enter but leave shaking their head. Will see what happens next few weeks into the 10-K due 3/1. There has been tons of volume since first of years so maybe something truly is up to support all those buyers. The ticker was big time over bought!
I would like to think things may be different this time.. but just as in last price spikes the lack of support (news/updates) from the company may put the ticker in same old pattern of less volume and slow price eroding. We will see in short order the direction. However, with all that has changed up since October you would think that Ridgeway or Inspyr or Hislop would speak up and give something to the stakeholders.
Up 12% OK by me.. was looking soft and could of tanked but didn't. Tomorrow another day.. lets see if the buyers are ready to step in and take this higher. Maybe first phase of flippers took their candy and left!
Seen this price action many time before.. nothing to get nervous about.. flippers can't stand prosperity. This stock will find its own value and price as we move forward.
WOW! WOW! WOW! What a way to start the week!
Original WSJ target was a Zacks investment price set at .85 a while back. after the 25-1 RS the price went to 21.25 then 637.50 after the 30-1 RS. Neither WSJ or Zacks have updated a new price target after last RS. However the orginal Zacks price of .85 is not a bad number for NSPX moving forward.
Adding to the commercial production of Thapsigargin, Phyton Biotech was granted patent by the USPTO on 11/03/20 for "The Production of Thapsigargin by Thapsia Cell Suspension Culture". By the same production process Phyton became the worlds largest producer of Taxol a standard in chemo drugs.
Buyers lining up for this ticker!
The positive view is that Inspyr's drug platforms will show value and additional investment will be needed to take the company to higher value. The negative is that the shares are needed to pay off convertible notes by existing investors and will result in dilution and a RS at a later date. Take your pick!
If the buy interest lately is a omen of things to come there may be positives moving forward. Hard to pinpoint what will be the catalyst. Both adenosine and thapsigargin based drug platforms are possible candidates and with the capability of microparticle technology for both platforms a substantial event my surface from either/or drugs.
Thx saw the article..could be very promising if you own a patent on a Thapsigargin based prodrug (mipsagargin) that is already proven to be effective and safe and is ready for ph III trials.
Although the focus of Inspyr is currently on RT-AR001 there comes now and then bits and pieces of research studies and/or articles concerning the medical prowess of thapsigargin. Genspera/Inspyr spent a lot of money and energy developing the thapsigargin based prodrug mipsagargin only to shelve it and move on to other drug platforms. Mipsagargin carries an orphan drug designation until 2034 has stage II clinical trial data so don't be surprised if something comes forward concerning mipsagargin.
Agreed.. Lots of volume lately.. A little research on historical prices and the study of this tickers price movements will clearly tell what is in store when news/updates come from the company. It rallies fast and rallies hard. Zero, Zilch, Nada reason do think its not going to happen again!
Nothing new.. Form D.. some required forms concerning unsolicited investments specifically outlined in 8-Ks for 10/5/20, 10/23/20 and 1/12/21. 10/05 was 65,000,000 common + 8000 preferred to Ridgeway. 10/23 was 600,000 cash for convertible debentures and 1/12 was 500,000 cash for convertibles. NSPX continues to get things in order.